Literature DB >> 10798271

Endothelial function and hemostasis.

B F Becker1, B Heindl, C Kupatt, S Zahler.   

Abstract

The vascular endothelium influences not only the three classically interacting components of hemostasis: the vessel, the blood platelets and the clotting and fibrinolytic systems of plasma, but also the natural sequelae: inflammation and tissue repair. Two principal modes of endothelial behaviour may be differentiated, best defined as an anti- and a prothrombotic state. Under physiological conditions endothelium mediates vascular dilatation (formation of NO, PGI2, adenosine, hyperpolarizing factor), prevents platelet adhesion and activation (production of adenosine, NO and PGI2, removal of ADP), blocks thrombin formation (tissue factor pathway inhibitor, activation of protein C via thrombomodulin, activation of antithrombin III) and mitigates fibrin deposition (t- and scuplasminogen activator production). Adhesion and transmigration of inflammatory leukocytes are attenuated, e.g. by NO and IL-10, and oxygen radicals are efficiently scavenged (urate, NO, glutathione, SOD). When the endothelium is physically disrupted or functionally perturbed by postischemic reperfusion, acute and chronic inflammation, atherosclerosis, diabetes and chronic arterial hypertension, then completely opposing actions pertain. This prothrombotic, proinflammatory state is characterised by vaso-constriction, platelet and leukocyte activation and adhesion (externalization, expression and upregulation of von Willebrand factor, platelet activating factor, P-selectin, ICAM-1, IL-8, MCP-1, TNF alpha, etc.), promotion of thrombin formation, coagulation and fibrin deposition at the vascular wall (expression of tissue factor, PAI-1, phosphatidyl serine, etc.) and, in platelet-leukocyte coaggregates, additional inflammatory interactions via attachment of platelet CD40-ligand to endothelial, monocyte and B-cell CD40. Since thrombin formation and inflammatory stimulation set the stage for later tissue repair, complete abolition of such endothelial responses cannot be the goal of clinical interventions aimed at limiting procoagulatory, prothrombotic actions of a dysfunctional vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798271     DOI: 10.1007/pl00007320

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  16 in total

Review 1.  Age-related endothelial dysfunction : potential implications for pharmacotherapy.

Authors:  Rachel L Matz; Ramaroson Andriantsitohaina
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

2.  A fatal consequence of acute myocardial infarction in a patient with APC-resistance at high altitude.

Authors:  U Kappert; M Wilbring; S M Tugtekin; K Alexiou; K Matschke
Journal:  Clin Res Cardiol       Date:  2008-02-22       Impact factor: 5.460

3.  Effects of analgesic use on inflammation and hematology in a murine model of venous thrombosis.

Authors:  Gerald A Hish; Jose A Diaz; Angela E Hawley; Daniel D Myers; Patrick A Lester
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

Review 4.  Role of tissue factor in venous thrombosis.

Authors:  David A Manly; Jeremiah Boles; Nigel Mackman
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

5.  Vascular endothelial functions, carotid intima-media thickness, and soluble CD40 ligand levels in dipper and nondipper essential hypertensive patients.

Authors:  Emin Alioglu; Ugur O Turk; Firat Bicak; Istemihan Tengiz; Dincer Atila; Vatan Barisik; Ertugrul Ercan; Mustafa Akin
Journal:  Clin Res Cardiol       Date:  2008-03-17       Impact factor: 5.460

Review 6.  Myocardial protection by nitrite.

Authors:  John W Calvert; David J Lefer
Journal:  Cardiovasc Res       Date:  2009-02-27       Impact factor: 10.787

Review 7.  Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease.

Authors:  D Lominadze; W L Dean; S C Tyagi; A M Roberts
Journal:  Acta Physiol (Oxf)       Date:  2009-09-01       Impact factor: 6.311

Review 8.  Antithrombin III for critically ill patients.

Authors:  Mikkel Allingstrup; Jørn Wetterslev; Frederikke B Ravn; Ann Merete Møller; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2016-02-08

9.  An absence of platelet activation following thalidomide treatment in vitro or in vivo.

Authors:  Jianlin Qiao; Yulu Wu; Xiaoqing Wu; Yun Liu; Xiaoqian Li; Wen Ju; Kunming Qi; Depeng Li; Elizabeth E Gardiner; Robert K Andrews; Lingyu Zeng; Kailin Xu
Journal:  Oncotarget       Date:  2017-05-30

10.  In situ re-endothelialization via multifunctional nanoscaffolds.

Authors:  Lee-Chun Su; Hao Xu; Richard T Tran; Yi-Ting Tsai; Liping Tang; Subhash Banerjee; Jian Yang; Kytai T Nguyen
Journal:  ACS Nano       Date:  2014-09-15       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.